Pfizer Inc. (NYSE:PFE) Shares Purchased by HF Advisory Group LLC

HF Advisory Group LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 20.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 67,611 shares of the biopharmaceutical company’s stock after acquiring an additional 11,479 shares during the period. Pfizer makes up approximately 1.2% of HF Advisory Group LLC’s portfolio, making the stock its 22nd largest position. HF Advisory Group LLC’s holdings in Pfizer were worth $1,947,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. grew its position in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after buying an additional 1,365,295 shares during the period. LifePlan Financial LLC purchased a new position in Pfizer during the fourth quarter valued at $255,000. Brookstone Capital Management lifted its holdings in Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares in the last quarter. ETF Store Inc. lifted its holdings in Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 727 shares in the last quarter. Finally, KLCM Advisors Inc. lifted its holdings in Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after purchasing an additional 74,487 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on PFE shares. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Stock Down 0.1 %

Pfizer stock traded down $0.03 during trading on Thursday, reaching $25.39. The stock had a trading volume of 5,543,254 shares, compared to its average volume of 42,064,246. Pfizer Inc. has a 52-week low of $25.26 and a 52-week high of $40.56. The business has a 50 day moving average price of $27.19 and a 200 day moving average price of $28.76. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market cap of $143.77 billion, a PE ratio of 70.57, a P/E/G ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.14 EPS. On average, analysts predict that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.